Literature DB >> 23407676

Cerebellar ataxia, hemiplegic migraine, and related phenotypes due to a CACNA1A missense mutation: 12-year follow-up of a large Portuguese family.

José Barros1, Joana Damásio, Assunção Tuna, Ivânia Alves, Isabel Silveira, José Pereira-Monteiro, Jorge Sequeiros, Isabel Alonso, Alda Sousa, Paula Coutinho.   

Abstract

OBJECTIVE: To document and discuss the broad phenotypic variability in a Portuguese family with cerebellar ataxia, hemiplegic migraine, and related syndromes caused by missense mutation c.1748 (p.R583Q) in the CACNA1A gene.
DESIGN: Observational 12-year follow-up study.
SETTING: Community and hospital care. PATIENTS: Sixteen patients in a 4-generation family were identified in 1998 in a population-based survey. The follow-up revealed 28 patients (25 of whom were observed) and 32 unaffected relatives with an a priori risk of 50%.
RESULTS: Four major phenotypes (migraine with multiple auras, transient focal neurological deficits without headache, coma triggered by minor head trauma, and slowly progressive cerebellar ataxia) were present in various combinations. The initial manifestation was ataxia in 16 patients and a transient episode in 12 patients. Eighteen patients did not have migraine, and 11 showed only ataxia. The c.1748 (p.R583Q) mutation in CACNA1A was confirmed in all 23 of the patients who were tested but was not found in any of the 27 adult relatives. The CACNA1A CAG repeat expansion was excluded.
CONCLUSIONS: A unique missense mutation in the CACNA1A gene, which exhibits a very high penetrance and expressivity, may present a phenotypic spectrum that is broader than current descriptions. Single-gene disorders can behave as complex traits, which reinforces the importance of genetic modifiers in the tightly regulated function of P/Q-type calcium channels. The clinical spectrum of missense mutation CACNA1A -related disorders is much broader than strictly familial hemiplegic migraine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23407676     DOI: 10.1001/jamaneurol.2013.591

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  6 in total

Review 1.  The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias.

Authors:  Stefan Kipfer; Michael Strupp
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

Review 2.  Vestibular Migraine: Clinical Challenges and Opportunities for Multidisciplinarity.

Authors:  Isabel Luzeiro; Leonel Luís; Freire Gonçalves; Isabel Pavão Martins
Journal:  Behav Neurol       Date:  2016-12-19       Impact factor: 3.342

3.  An altered GABA-A receptor function in spinocerebellar ataxia type 6 and familial hemiplegic migraine type 1 associated with the CACNA1A gene mutation.

Authors:  Satoshi Kono; Tatsuhiro Terada; Yasuomi Ouchi; Hiroaki Miyajima
Journal:  BBA Clin       Date:  2014-09-28

4.  Monozygotic twin sisters discordant for familial hemiplegic migraine.

Authors:  José Barros; Rui Barreto; Ana Filipa Brandão; Joana Domingos; Joana Damásio; Cristina Ramos; Carolina Lemos; Jorge Sequeiros; Isabel Alonso; José Pereira-Monteiro
Journal:  J Headache Pain       Date:  2013-09-16       Impact factor: 7.277

5.  Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy.

Authors:  Mercè Izquierdo-Serra; Antonio F Martínez-Monseny; Laura López; Julia Carrillo-García; Albert Edo; Juan Darío Ortigoza-Escobar; Óscar García; Ramón Cancho-Candela; M Llanos Carrasco-Marina; Luis G Gutiérrez-Solana; Daniel Cuadras; Jordi Muchart; Raquel Montero; Rafael Artuch; Celia Pérez-Cerdá; Belén Pérez; Belén Pérez-Dueñas; Alfons Macaya; José M Fernández-Fernández; Mercedes Serrano
Journal:  Int J Mol Sci       Date:  2018-02-22       Impact factor: 5.923

6.  Functional gene networks reveal distinct mechanisms segregating in migraine families.

Authors:  Andreas H Rasmussen; Lisette J A Kogelman; David M Kristensen; Mona Ameri Chalmer; Jes Olesen; Thomas Folkmann Hansen
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.